At a Glance
Yatharth Hospital just dropped a healthy Q1 FY26 report – Revenue up 22%, PAT up 40%, and occupancy in its flagship Noida hospitals remains robust. The stock pumped +5.2% to ₹685 as investors cheered the growth in a sector where valuations are already hotter than a fever ward. With new beds coming online and margins stable, Yatharth is flexing, but at 46× P/E, you’re paying ICU rates for general ward services.
Introduction
In the overcrowded hospital stock market, Yatharth is the new-age multi-specialty player trying to elbow its way past Apollo and Max. With seven hospitals (and counting), 87% of beds in metro locations, and occupancy creeping higher, the company is scaling up fast. Yet, while doctors save lives, can this stock save portfolios from the plague of high valuations?
Business Model (WTF Do They Even Do?)
Yatharth runs multi-specialty hospitals focused on trauma care, cardiology, neurology, orthopedics, and critical care.
- Bed Strength: ~1,605 operational across 7 hospitals.
- Revenue Streams: In-patient, diagnostics, surgeries, pharmacy.
- USP: High proportion of ICU beds (over 400) and strong metro presence.
Roast: They make money when patients are sick, but investors are praying for a healthy earnings trend.
Financials Overview
Q1 FY26 Highlights
- Revenue: ₹258 Cr (+22% YoY)
- Operating Profit: ₹64 Cr (OPM 25%)
- Net Profit: ₹42 Cr (+40% YoY)
- EPS: ₹4.36
FY25 Performance
- Revenue: ₹926 Cr
- PAT: ₹142 Cr
- ROE: 10.5%
- ROCE: 13.8%
Takeaway: Growth is strong, margins stable, and PAT scaling faster than revenue –
